Table 1 Basic characteristics of the included studies.
From: Clinicopathological Significance and Potential Drug Target of CDKN2A/p16 in Endometrial Carcinoma
Study | Country | No. of EC tissue/control | Methods | Methylation site | CDKN2A expression |
|---|---|---|---|---|---|
Zhang et al. 201128 | China | 35/15 | MSP | Promoter, CpG islands | − |
Zhou et al. 200929 | China | 38/20 | MSP | Exon 1 | − |
Guida et al. 200930 | Italy | 40/25 | MSP | Promoter, CpG islands | − |
Ignatov et al. 200822 | Germany | 54/ND | MSP/IHC | Promoter, CpG islands | + |
Suehiro et al. 200821 | Japan | 103/27 | MSP | Promoter, CpG islands | − |
Yang et al. 200626 | China | 134/ND | MSP | Promoter, CpG islands | − |
Yun et al. 200431 | China | 62/10 | MSP | Exon 1 | + |
Semczuk et al. 200323 | Poland | 11/ND | MSP/IHC | Promoter, CpG islands | + |
Wang et al. 200224 | China | 36/12 | MSP | Exon 1 | − |
Chao et al. 200027 | China | 48/14 | MSP, RT-PCR | Exon 1 | + |
Zhao et al. 200032 | China | 38/8 | MSP, RT-PCR | Exon 1 | + |
Wong et al. 199925 | Hong Kong | 49/ND | MSP | Promoter, CpG islands | − |
